Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials
Gross G, Jaccaud E, Huggett AC (1997)
Significant distinctions were found between responders and non (or poor) responders with responders achieving greater weight loss of (7.38 1.74 kg vs 2.11 2.17kg, respectively)
The second is simpler
A comparative study of the BPC 157 beneficial effect was done with intraperitoneal application, once daily, intraperitoneally (per kg body weight) 10 g, 10 ng, or 10 pg BPC 157, while standard agents 10 mg atropine, 50 mg ranitidine, and 50 mg omeprazole provide only a weak effect
No doubt 5 star treatment here